 Notes from the East Woods musings on opportunities in the life science marketplace June 2012
|
|
|
| Greetings! |
Though crossing into new markets is a great strategy, it can be a little tricky. Please have a read and feel free to let me know what you think.
Regards,
Paul Danis Founder and Principal
|
|
|
|
|
|
Chipmunks, Roads and New Markets
|

As I swerved to avoid the chipmunk crossing the road, I felt the unmistakable soft thump as he went off to meet his maker. I felt bad about this as these cute creatures are relatively benign and fun to watch. He just picked an inopportune time to seek out the spoils on the other side. A similar fate sometimes befalls companies that urgently try to get to new markets. Though a tried and true growth strategy with new or current products, it is usually more challenging than initially thought.
There are two general ways to get to the greener pastures - the first is to spend the time and energy($) to determine exactly where your product will be well-received and then figure out precisely how to get there. The second is a more empirical path where you have reasonable confidence that you will be successful, but release the product with the expectation of garnering valuable feedback which you will then use to make the final (wildly successful) product. Which of these avenues you choose stems, to a large degree, from the capabilities and nature of your organization.
- If you tend to be risk averse (be honest here), then by all means do a lot of due diligence before you push the go button. However, if you can live with some uncertainty and occasional failure, then the two-step process may be for you.
- Having the ability to rapidly turn around product enhancements is also critical to empirical marketing. If it takes you 9 months to update a manual, then stick with the heavy up-front strategy development.
- Finally can the business tolerate a shaky forecast? If you are hanging your overall success on this product meeting your initial forecast, then certainly the conservative approach is best. If you have great cash flow and having a low forecast or missing it is tolerable, then go ahead and do the launch and learn.
Finally no matter whether you have complete confidence in this product or are just testing the waters, good execution is paramount. Having a good plan and doing it well are often the most important determinants of success (or failure). For it is likely that the little chipmunk had a well-conceived plan for building a new home in the roots of the old maple, he just executed poorly and chose the wrong time to cross the road.
|
Life Science Market Update
|
|
Index
|
Apr. Value
|
Change 12mo.
|
12 mo. High
|
12 mo. Low
| |
EC BioTools
|
587
|
-19%
|
722
|
532
| |
EC BigPharma
|
879
|
-6%
|
953
|
821
| |
EC Biotech
|
800
|
9%
|
810
|
624
|
The Tools sector was down 5% for the month with weakness across the board. BigPharma likewise dove down 8% for the month on somewhat cautionary sentiments. An example is Teva down 14% for the month after they announced 25% increase in sales which was characterized as "disappointing," and was subsequently downgraded. Biotech was relatively flat for the month, which as surprising considering the wild swings of Vertex and Dendreon. Dendreon fell 40% for the month on weak earnings and concerns about future sales of their prostate cancer therapy Provenge. Vertex, on the other hand, was up 56% following the release of positive interim data from a mid-stage study of its combination therapy for cystic fibrosis. EC BioIndex June 2012
---------------------
Many of the life science indices currently available are a mixture of various types of companies. In order to better assess the situation in the different segments, Eastwoods Consulting has created these price-weighted indices for the sectors of large pharmaceutical companies, biotech companies, and life science research tools companies.
- EC BioTools Index - A, ACCL, AFFX, BIO, BRKR, HBIO, ILMN, LIFE, LMNX, PKI, QGEN, SIAL, TECH, TMO, WAT
- EC BigPharma Index - JNJ, PFE, GSK, NVS, SNY, LUN, ABT, LLY, AZN, WYE, BMY, NVO, BAX, TEVA, VRX.TO, ROG.VX
- EB Biotech Index - ALKS, AMGN, AMLN, BIIB,BMRN, CPHD, DNDN, GILD, HGSI, IDXX, ITMN, NKTR, PDLI, REGN, SGMO, SHPGY, THRX, VRTX
- Prices are taken at the close of each month.
|
|
| About Eastwoods Consulting
|
Translating Innovations into Profits for the Life Science IndustrysmEastwoods Consulting helps life science companies grow their businesses. Please visit our web site or contact us to learn more about how we help companies succeed in competitive markets.
|
Copyright © 2012, Eastwoods Consulting. This publication may be freely redistributed in full or in part as long as full attribution including our contact information and web address, are included. Eastwoods is a registered servicemark of Eastwoods Consultng.
|
|
|
|
|